Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ia, Double-blind, Randomized, Placebo-controlled, Ascending IV Single-dose Study to Evaluate the Safety and Pharmacokinetics of ch mAb7F9 in Healthy Subjects

NCT01603147 is registered in ClinicalTrials.gov with InterveXion Therapeutics, LLC as lead sponsor.

NCT NCT01603147
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01603147 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ia, Double-blind, Randomized, Placebo-controlled, Ascending IV Single-dose Study to Evaluate the Safety and Pharmacokinetics of ch mAb7F9 in Healthy Subjects
Lead sponsor
InterveXion Therapeutics, LLC
Phase
Phase 1
Overall status
Completed
Start date
April 30, 2012
Completion date
July 31, 2013
Enrollment
42 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

methamphetamine abuse